Potential overtreatment of type 2 diabetes therapy in real clinical practice: Omsk Oblast register data
https://doi.org/10.14341/DM12469
Abstract
Backgraund: The total number of patients with type 2 diabetes mellitus (T2DM) in the Russian Federation as of 01.01.2019 is 4.24 million. The majority of patients with T2DM are elderly people and older, forming groups with high comorbidity and the risk of severe hypoglycemia, including those associated with excess hypoglycemic therapy. Foreign studies indicate that a significant proportion of older adults with diabetes are potentially exposed to excessive sugar-lowering therapy.
Aims: to study the frequency of excessive decrease in HbA1c in a group of patients with T2DM according to a sample from the regional diabetes register.
Materials and methods: A content analysis of the regional register of diabetes mellitus was carried out as of December 31, 2019. Based on the register data, an individual target level of HbA1c was calculated and the compliance of the achieved HbA1c level with the target level was assessed.
Results: The analysis included data from 1202 patients with T2DM, which amounted to 2.35% of the total number of patients with T2DM in the region (n = 51,163). The age of the included individuals was 66 years (LQ 60.0; UQ 72), 360 men (29.95%). The duration of T2DM 8.0 years. The HbA1c level in the general group was 7.1%. Persons over 60 years of age accounted for 75.21% (n = 904). When analyzing HbA1c in the age groups, there were no statistically significant differences (p> 0.05). HbA1c was above the target level in 43.34% of cases (n = 521). The level of HbA1c <6.5% was noted in a quarter of cases (24.62%), including HbA1c <6.0% was recorded in 97 cases, which accounted for a third of all cases of tight glycemic control. At the same time, the majority of observations of HbA1c <6.5% were in patients 60 years and older (79.73%). Among young and middle-aged patients with HbA1c <6.5%, 8.33% of cases had risk factors for severe hypoglycemia in the presence of SU and / or insulin therapy. In the older age group (in comparison with young and middle-aged patients), HbA1c <7% (p <0.05) was significantly more often detected, there was a tendency for a higher frequency of HbA1c <6.5% (p = 0.067). Among elderly and senile patients with HbA1c <6.5%, in 41.53% of cases there were risk factors for severe hypoglycemia, in a quarter of cases in T2DM therapy SU and / or insulin were used (24.58%), almost every fifth patient (19.07%), risk factors for severe hypoglycemia, received SU and / or insulin.
Conclusion: According to our data, at least a quarter of patients in the older age group (24.58%) had overtreatment and need de-intensification of therapy. Perhaps that in this group of patients, the risks associated with treatment may outweigh the benefits of tight glycemic control, and these patients require planned de-intensification of glucose-lowering therapy. Taking into account the position of some expert communities on determining the target range of HbA1c in the older age group, the need for de-intensification of antihyperglycaemic therapy may be even higher. Further research is required in order to develop a full-fledged domestic concept of de-intensification of hypoglycemic therapy.
About the Authors
I. V. DrukRussian Federation
Inna V. Druk, MD, PhD, associate professor; eLibrary SPIN: 9069-1518.
12 Lenina street, 644009 Omsk
Competing Interests:
The author declares the absence of obvious and potential conflicts of interest related to the publication of this article
D. I. Snarskaya
Russian Federation
Diana I. Snarskaya - graduate student
Competing Interests:
The author declares the absence of obvious and potential conflicts of interest related to the publication of this article
O. I. Goroshchenya
Russian Federation
Oksana I. Goroshchenya - Head of Endocrinology Department
Competing Interests:
The author declares the absence of obvious and potential conflicts of interest related to the publication of this article
References
1. Shestakova MV, Vikulova OK, Zheleznyakova AV, et al. Diabetes epidemiology in Russia: what has changed over the decade? Therapeutic Archive. 2019;91(10):4-13. (In Russ.). doi: https://doi.org/10.26442/00403660.2019.10.000364
2. Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Ed. by Dedov II, Shestakova MV, Mayorov AY. 9th edition. Diabetes Mellitus. 2019;22(S1-1):1–144. (In Russ.). doi: https://doi.org/10.14341/DM221S1
3. Dedov II, Shestakova MV, Vikulova OK, et al. Atlas of the diabetes register of the Russian Federation. Status 2018. Diabetes Mellitus. 2019;22(2S):4−61. (In Russ.). doi: https://doi.org/10.14341/DM12208
4. Lipska KJ, Ross JS, Miao Y, et al. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015;175(3):356‐362. doi: https://doi.org/10.1001/jamainternmed.2014.7345
5. Sonmez A, Tasci I, Demirci I, et al. A Cross-Sectional Study of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Diabetes Mellitus: The TEMD Overtreatment Study. Diabetes Ther. 2020;11(5):1045‐1059. doi: https://doi.org/10.1007/s13300-020-00779-0
6. McAlister FA, Youngson E, Eurich DT. Treatment Deintensification Is Uncommon in Adults With Type 2 Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2017;10(4). doi: https://doi.org/10.1161/CIRCOUTCOMES.116.003514
7. Makam AN, Nguyen OK. An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment. Circulation. 2017;135(2):180‐195. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.022622
8. McAlister FA, Youngson E, Eurich DT. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362(17):1575-1585. doi: https://doi.org/10.1056/NEJMoa1001286
9. McAlister FA, Youngson E, Eurich DT. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008;358(24):2545-2559. doi: https://doi.org/10.1056/NEJMoa0802743
10. McAlister FA, Youngson E, Eurich DT. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008;358(24):2560-2572. doi: https://doi.org/10.1056/NEJMoa0802987
11. Duckworth W, Abraira C, Moritz T, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009;360(2):129-139. doi: https://doi.org/10.1056/NEJMoa080843
12. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343(24-1):d6898-d6898. doi: https://doi.org/10.1136/bmj.d6898
13. Rodríguez-Gutiérrez R, Montori VM. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes. 2016;9:504-512. doi: https://doi.org/10.1161/CIRCOUTCOMES.116.002901
14. American Diabetes Association. Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(1):S1–S212.
15. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-2498. doi: https://doi.org/10.1007/s00125-018-4729-5
16. Tseng CL, Soroka O, Maney M, et al. Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med. 2014;174(2):259-268. doi: https://doi.org/10.1001/jamainternmed.2013.12963
17. Lipska KJ, Warton EM, Huang ES, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care. 2013;36(11):3535-3542. doi: https://doi.org/10.2337/dc13-0610
18. Davis TM, Brown SG, Jacobs IG, et al. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab. 2010;95(5):2240-2247. doi: https://doi.org/10.1210/jc.2009-2828
19. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559. doi: https://doi.org/10.1056/NEJMoa0802743
20. Zoungas S, Chalmers J, Neal B, et al. ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371:1392-1406. doi: https://doi.org/10.1056/NEJMoa1407963
21. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-2298. doi: https://doi.org/10.1007/s00125-009-1470-0
22. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765-1772. doi: https://doi.org/10.1016/S0140-6736(09)60697-8
23. Kelly TN. Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes. Ann Intern Med. 2009;151(6):394-403. doi: https://doi.org/10.7326/0003-4819-151-6-200909150-00137
24. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343(1):d4169-d4169. doi: https://doi.org/10.1136/bmj.d4169
25. Fox CS, Golden SH, Anderson C, et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care. 2015;38(9):1777-1803. doi: https://doi.org/10.2337/dci15-0012
26. Sonmez A, Tasci I, Demirci I, et al. A Cross-Sectional Study of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Diabetes Mellitus: The TEMD Overtreatment Study. Diabetes Ther. 2020;11(5):1045-1059. doi: https://doi.org/10.1007/s13300-020-00779-0
27. Pirela DV, GARG R. 399-P: Deintensification of Diabetes Treatment in Elderly Patients with Type 2 Diabetes Mellitus. Diabetes. 2019;68(1):399-P. doi: https://doi.org/10.2337/db19-399-P
28. Araki E, Goto A, Kondo T, et al. Japanese Clinical Practice Guideline for Diabetes 2019. J Diabetes Investig. 2020;11(4):1020-1076. doi: https://doi.org/10.1111/jdi.13306
29. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Guidelines Abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 Update. J Am Geriatr Soc. 2013;61(11):2020-2026. doi: https://doi.org/10.1111/jgs.12514
30. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1520-1574. doi: https://doi.org/10.1210/jc.2019-00198
31. Farrell B, Black C, Thompson W, et al. Deprescribing antihyperglycemic agents in older persons. Canadian Family Physician. 2017;63(11):832-843.
32. Klimontov VV. Impaired recognition of hypoglycemia in diabetes mellitus: epidemiology, mechanisms of development, therapeutic approaches. Diabetes mellitus. 2018;21(6):513-523. (In Russ.). doi: https://doi.org/10.14341/DM9597
33. Tkacheva ON, Ostroumova OD, Kotovskaya YuV, et al. Deprescribing of hypoglycemic drugs in elderly and senile patients: current state of the issue and review of the evidence base. Clinical pharmacology and therapy. 2019;28(3):62-67. (In Russ.). doi: https://doi.org/10.32756/0869-5490-2019-3-62-67
Supplementary files
Review
For citations:
Druk I.V., Snarskaya D.I., Goroshchenya O.I. Potential overtreatment of type 2 diabetes therapy in real clinical practice: Omsk Oblast register data. Diabetes mellitus. 2021;24(2):100-110. (In Russ.) https://doi.org/10.14341/DM12469

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).